Side-by-side · Research reference

KPVvsLiraglutide

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongDraft13/39 cited

BFDA-ApprovedVerified14/45 cited

KPV

α-MSH C-terminal · Anti-inflammatory

200–500 mcgDaily doseDalle-Pang 2024

AnimalEvidence levelDalle-Pang 2024

HoursHalf-life (est)

SQ / oral / topical · Local · Daily or 2-3×/week

Liraglutide

Daily GLP-1 RA · FDA-Approved

0.6–3.0 mgDaily doseSAXENDA (liraglutide) injectio 2014

5–10%Body-weight ↓SAXENDA (liraglutide) injectio 2014

~13 hrHalf-lifeSAXENDA (liraglutide) injectio 2014

SQ · Abdomen / thigh / arm · Once daily

01Mechanism of Action

Parameter

KPV

Liraglutide

Primary target

Intracellular targets bypassing melanocortin receptors (proposed)Dalle-Pang 2024

GLP-1 receptor (GLP-1R)SAXENDA (liraglutide) injectio 2014

Pathway

NF-κB inhibition + cytokine modulation (TNF-α, IL-1β, IL-6) → reduced inflammationDalle-Pang 2024

GLP-1R agonism → ↑glucose-dependent insulin, ↓glucagon, ↓gastric emptying, ↓appetiteSAXENDA (liraglutide) injectio 2014 Marso 2016

Downstream effect

Anti-inflammatory action without α-MSH pigmentation effects; gut barrier protectionDalle-Pang 2024

Glycemic improvement, modest body-weight reduction, cardiovascular event reduction in high-risk T2DMarso 2016

Feedback intact?

No melanocortin receptor binding

Glucose-dependent insulin release preserves physiological feedback

Origin

Synthetic tripeptide; the C-terminal Lys-Pro-Val residues of α-MSH (residues 11-13)Dalle-Pang 2024

Modified GLP-1(7-37) with Lys26 substitution (Arg34) and C-16 palmitoyl-glutamate acylation for albumin bindingSAXENDA (liraglutide) injectio 2014

Antibody development

—

02Dosage Protocols

Parameter

KPV

Liraglutide

Standard dose

200–500 mcg / day SQ or oralDalle-Pang 2024

—

Frequency

Daily or 2–3× per week

Once daily, same time each day

Lower / starter dose

100 mcg / day

—

Evidence basis

Animal-strong + emerging clinical data in IBDDalle-Pang 2024

FDA-approved · Phase 3 RCTs (LEADER, SCALE)Marso 2016 SAXENDA (liraglutide) injectio 2014

Duration

4–8 weeks per cycle

Indefinite for chronic indication

Reconstitution

Bacteriostatic water (SQ form)

Pre-filled commercial pen (no reconstitution)

Timing

No specific time; often taken with / before meals (oral)

Any time of day; consistent

Half-life

Hours (estimated; rapid tissue uptake)

~13 hrSAXENDA (liraglutide) injectio 2014

Standard dose (T2D, Victoza)

—

1.2–1.8 mg / daySAXENDA (liraglutide) injectio 2014

Standard dose (weight, Saxenda)

—

3.0 mg / day (after 5-week titration)SAXENDA (liraglutide) injectio 2014

Titration schedule

—

0.6 → 1.2 → 1.8 → 2.4 → 3.0 mg over 5 weeks

Mitigates GI side effects.

04Side Effects & Safety

Parameter

KPV

Liraglutide

Injection site reaction

Mild irritation

—

GI symptoms

Rare nausea (oral form)

Nausea, vomiting, diarrhea (very common during titration)SAXENDA (liraglutide) injectio 2014

Pigmentation

None (unlike full α-MSH)Dalle-Pang 2024

—

Long-term safety

Limited human data

—

Pregnancy / OB

Avoid — insufficient data

Contraindicated

Pancreatitis risk

—

Rare; discontinue if suspected

Thyroid C-cell tumours

—

Boxed warning — contraindicated in MEN2 / MTC historySAXENDA (liraglutide) injectio 2014

Hypoglycemia

—

Low risk as monotherapy; elevated with sulfonylureas / insulin

Heart rate

—

Modest ↑ resting HR (~2-3 bpm)

Cardiovascular benefit

—

↓ MACE in high-risk T2D (LEADER trial)Marso 2016

Absolute Contraindications

KPV

·Pregnancy / breastfeeding

Liraglutide

·MTC personal or family history; MEN2
·Pregnancy / breastfeeding
·Hypersensitivity to liraglutide

Relative Contraindications

KPV

·Active autoimmune disease (theoretical)

Liraglutide

·Severe gastroparesis
·History of pancreatitis
·Severe gastrointestinal disease

05Administration Protocol

Parameter

KPV

Liraglutide

1. Reconstitution

Add 1 mL bacteriostatic water to vial per labelling.

Commercial pre-filled pen, no reconstitution required.

2. Form

SQ injection (acute), oral capsule (chronic / gut), topical for skin indications.

SQ — abdomen, thigh, or upper arm. Rotate sites.

3. Timing

Morning preferred; oral form taken with / before meals.

Once daily, same time each day. Take with or without food.

4. Storage

Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.

Refrigerate 2–8 °C unopened; room temp ≤30 °C up to 30 days after first use.

5. Needle

29–31G insulin syringe (SQ form).

Pen-supplied 32G needle.

06Stack Synergy

KPV

+ BPC-157

Strong

View BPC-157 →

KPV (NF-κB inhibition, cytokine reduction) + BPC-157 (VEGF-driven angiogenesis, tissue regeneration) form the classic gut-healing stack. KPV reduces inflammatory drive; BPC-157 promotes mucosal repair. Anecdotally favoured for IBD, ulcerative colitis, and post-surgical gut recovery.

KPV: 200–500 mcg oral · daily
BPC-157: 250–500 mcg oral or SQ · daily
Primary benefit: Combined anti-inflammation + mucosal repair for gut conditions

Dalle-Pang 2024 Sikiric 2018

Liraglutide

— no documented stacks